NASDAQ:ATNF

180 Life Sciences (ATNF) Stock Forecast, Price & News

$1.16

-0.03 (-2.52%)

(As of 03:20 PM ET)

Compare

Today's Range: $1.13
▼
$1.24
50-Day Range: $0.97
▼
$1.95
52-Week Range: $0.94
▼
$39.80

Volume: 97,987 shs
Average Volume: 1.85 million shs
Market Capitalization: $4.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

180 Life Sciences MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.96% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.67
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$65,421 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for 180 Life Sciences.

5.0

Short Interest

Percentage of Shares Shorted
1.96% of the float of 180 Life Sciences has been sold short.
Short Interest Ratio / Days to Cover
180 Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in 180 Life Sciences has recently decreased by 13.19%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
180 Life Sciences does not currently pay a dividend.
Dividend Growth
180 Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATNF.

3.1

News and Social Media Coverage

News Sentiment
180 Life Sciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for 180 Life Sciences this week, compared to 1 article on an average week.
Search Interest
Only 8 people have searched for ATNF on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
MarketBeat Follows
5 people have added 180 Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 180 Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,421.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.90% of the stock of 180 Life Sciences is held by insiders.
Percentage Held by Institutions
Only 15.30% of the stock of 180 Life Sciences is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of 180 Life Sciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 180 Life Sciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
180 Life Sciences has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About 180 Life Sciences (NASDAQ:ATNF) Stock

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

Receive ATNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ATNF Stock News Headlines

May 30, 2023 | americanbankingnews.com

Analyzing Antibe Therapeutics (OTCMKTS:ATBPD) & 180 Life Sciences (NASDAQ:ATNF)

May 21, 2023 | americanbankingnews.com

Insider Buying: 180 Life Sciences Corp. (NASDAQ:ATNF) CEO Buys 40,000 Shares of Stock

June 2, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.

April 27, 2023 | americanbankingnews.com

180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Update

April 17, 2023 | americanbankingnews.com

180 Life Sciences Corp. (NASDAQ:ATNF) Sees Significant Increase in Short Interest

April 10, 2023 | finance.yahoo.com

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

April 5, 2023 | finance.yahoo.com

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

April 5, 2023 | investorplace.com

Why Is 180 Life Sciences (ATNF) Stock Up 30% Today?

June 2, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

February 28, 2023 | finance.yahoo.com

180 Life Sciences Announces Presentation at the Gordon Conference

February 27, 2023 | finance.yahoo.com

180 Life Sciences Announces Presentation at the Gordon Conference

February 23, 2023 | finance.yahoo.com

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application

February 23, 2023 | seekingalpha.com

180 Life Sciences stock dips as recruitment in trial for Frozen shoulder closes amid challenges

February 23, 2023 | seekingalpha.com

180 Life Sciences to get US patent linked to treating hand disorder Dupuytren

February 23, 2023 | finance.yahoo.com

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application

February 22, 2023 | benzinga.com

180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial

February 22, 2023 | finance.yahoo.com

180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial

January 25, 2023 | finance.yahoo.com

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease

January 25, 2023 | msn.com

180 Life Sciences up 12% on tumor necrosis factor as target for Dupuytren’s disease

January 25, 2023 | finance.yahoo.com

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease

January 17, 2023 | finance.yahoo.com

180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom

January 10, 2023 | wsj.com

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

January 5, 2023 | finance.yahoo.com

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

January 4, 2023 | au.finance.yahoo.com

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease

January 4, 2023 | finance.yahoo.com

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease

January 3, 2023 | benzinga.com

Thinking about buying stock in Mullen Automotive, SWVL Holdings, 180 Life Sciences, Alibaba, or Pinterest?

December 23, 2022 | finance.yahoo.com

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

See More Headlines

ATNF Price History

30 days | 90 days | 365 days | Advanced Chart

ATNF Company Calendar

Today: 6/02/2023
Next Earnings (Estimated): 6/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ATNF
CUSIP: N/A
CIK: 1690080
Web: www.kblmerger.com
Phone: (650) 507-0669
Fax: N/A
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -119.88%
Return on Assets: -85.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.82
Quick Ratio: 0.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.72 per share
Price / Book: 0.69

Miscellaneous

Outstanding Shares: 4,150,000
Free Float: 3,902,000
Market Cap: $4.94 million
Optionable: Not Optionable
Beta: 0.53

Key Executives

Jim N. Woody
Chief Executive Officer & Director

Ozan Pamir
Chief Financial Officer

Jonathan B. Rothbard
Chief Scientific Officer

Jason Assad
Director-Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATNF Stock - Frequently Asked Questions

Should I buy or sell 180 Life Sciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 180 Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATNF shares.
View ATNF analyst ratings or view top-rated stocks.
How have ATNF shares performed in 2023?: 180 Life Sciences' stock was trading at $3.39 at the start of the year. Since then, ATNF shares have decreased by 64.9% and is now trading at $1.19.
View the best growth stocks for 2023 here.
Are investors shorting 180 Life Sciences?: 180 Life Sciences saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 95,400 shares, a drop of 13.2% from the April 30th total of 109,900 shares. Based on an average daily volume of 871,400 shares, the short-interest ratio is presently 0.1 days. Approximately 2.0% of the shares of the stock are sold short.
View 180 Life Sciences' Short Interest.
When is 180 Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023.
View our ATNF earnings forecast.
When did 180 Life Sciences' stock split?: 180 Life Sciences shares reverse split before market open on Monday, December 19th 2022. The 1-20 reverse split was announced on Monday, December 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is 180 Life Sciences' stock symbol?: 180 Life Sciences trades on the NASDAQ under the ticker symbol "ATNF."
Who are 180 Life Sciences' major shareholders?: 180 Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.06%), Cubist Systematic Strategies LLC (0.63%), Two Sigma Investments LP (0.38%) and Simplex Trading LLC (0.00%). Insiders that own company stock include James N Woody, Jr Donald A Mcgovern, Marlene Krauss, Ozan Pamir, Pamela G Marrone and Quan Anh Vu.
View institutional ownership trends.
How do I buy shares of 180 Life Sciences?: Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is 180 Life Sciences' stock price today?: One share of ATNF stock can currently be purchased for approximately $1.19.
How much money does 180 Life Sciences make?: 180 Life Sciences (NASDAQ:ATNF) has a market capitalization of $4.94 million. The company earns $-38,730,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis.
How can I contact 180 Life Sciences?: 180 Life Sciences' mailing address is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. The official website for the company is www.kblmerger.com. The company can be reached via phone at (650) 507-0669 or via email at jason@180lifesciences.com.

This page (NASDAQ:ATNF) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial